NCT05672420 is a Phase 1, PHASE2 clinical trial of umbilical cord derived mesenchymal stem cells in Hematologic Neoplasms, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

What drugs are being tested in NCT05672420?

Interventions in NCT05672420: umbilical cord derived mesenchymal stem cells.

What condition does NCT05672420 study?

NCT05672420 studies Hematologic Neoplasms, Neutropenia, Anemia, Thrombocytopenia, Infections, Bleeding.

Is NCT05672420 still recruiting?

NCT05672420 is currently status unknown. Last updated 5 January 2023.

Last reviewed 2023-01-05 · How we verify

NCT05672420

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies

Status unknown Phase 1, PHASE2 Last updated 5 January 2023

What this trial tests

Phase 1, PHASE2 trial testing umbilical cord derived mesenchymal stem cells in Hematologic Neoplasms in 181 participants. Status unknown.

Timeline

1 January 2023

Primary endpoint
31 December 2023

31 January 2025

Quick facts

Lead sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	181
Start date	1 January 2023
Primary completion	31 December 2023
Estimated completion	31 January 2025
Sites	3 locations across China

Drugs / interventions tested

umbilical cord derived mesenchymal stem cells

Conditions studied

Hematologic Neoplasms — all drugs for Hematologic Neoplasms →
Neutropenia — all drugs for Neutropenia →
Anemia — all drugs for Anemia →
Thrombocytopenia — all drugs for Thrombocytopenia →

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Who can join

Adults 18 to 75, any sex, with Hematologic Neoplasms or Neutropenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to explore the safety and efficacy of umbilical cord derived mesenchymal stem cells in treatment-induced myelosuppression in patients with hematologic malignancies.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Stromal cells in the tumor microenvironment: accomplices of tumor progression?
Zhao Y, Shen M, Wu L, Yang H, et al · · 2023 · cited 271× · PMID 37666813 · DOI 10.1038/s41419-023-06110-6
The Role of Mesenchymal Stem Cells in Modulating the Breast Cancer Microenvironment.
Zhang L. · · 2023 · cited 17× · PMID 38135917 · DOI 10.1177/09636897231220073
Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options.
Mello DB, Mesquita FCP, Silva Dos Santos D, Asensi KD, et al · · 2024 · cited 15× · PMID 38892249 · DOI 10.3390/ijms25116063
Bioinspired micro- and nanostructured systems for cancer therapy.
Yang R, Zhang B, Fei X, Cong S, et al · · 2024 · cited 1× · PMID 39619230 · DOI 10.1002/mco2.70025
Mesenchymal Stem Cells in Myelodysplastic Syndromes and Leukaemia.
Eroz I, Kakkar PK, Lazar RA, El-Jawhari J. · · 2024 · cited 1× · PMID 39200142 · DOI 10.3390/biomedicines12081677
Mesenchymal Stromal/Stem Cells (MSCs) in Cancer Therapy: Advanced Therapeutic Strategies Towards Future Clinical Translation.
Kucharczyk H, Tarnowski M, Tkacz M. · · 2025 · PMID 41471830 · DOI 10.3390/molecules30244808
Mesenchymal Stromal Cells: Bridging the Gaps in Hematologic Disease Therapy.
Zhao X, Ming X, Wu J, Zhu X, et al · · 2026 · PMID 41254448 · DOI 10.1007/s12015-025-11011-6

Verify or expand the search:

Other recruiting trials for Hematologic Neoplasms

Currently open trials in the same condition.

NCT07519811 — LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL) · NA · recruiting
NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting
NCT07162038 — Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA- · Phase 1 · recruiting
NCT06685848 — Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion · NA · recruiting
NCT06433349 — A Multi-center Investigation of Family Health. · recruiting

Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05672420 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Last refreshed: 5 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05672420.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing